Skip to main content

Advertisement

Figure 2 | Nutrition & Metabolism

Figure 2

From: Rosiglitazone decreases postprandial production of acylation stimulating protein in type 2 diabetics

Figure 2

ROSI effects on plasma TG and non-esterified fatty acids (NEFA): Following a standardized mixed meal, arterial TG (A), adipose venous TG (B), arterial NEFA (C) and adipose venous NEFA (D) were measured serially from 0 to 6 hours in control (n = 9), diabetics (n = 6) and diabetics treated with rosiglitazone (ROSI). Results are expressed as average ± sem with detailed statistics presented in the text, all comparisons used RM-ANOVA.

Back to article page